Can a single antibiotic dose cut child mortality in niger?

NCT ID NCT04224987

Completed Prevention Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial tests whether giving azithromycin—a common antibiotic—twice a year to young children in Niger can reduce deaths. It compares giving the drug to all children aged 1-59 months versus only to infants 1-11 months, who are at highest risk. The study also checks how these approaches affect antibiotic resistance. If targeting infants works, it could save lives while reducing the spread of resistant bacteria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: azithromycin (an antibiotic)
What this could lead to: If successful, this could support a simple, targeted antibiotic strategy to reduce child deaths in high-mortality regions while limiting antibiotic resistance.
What could go wrong: The trial is large but still a test—results may not confirm benefit, and antibiotic resistance remains a real risk with widespread use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILD, ONLY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

CHILD syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHILD, ONLY MORTALITY RESISTANCE BACTERIAL

Contacts and locations

Locations

Programme national de santé oculaire

Niamey, Niger

More trials for these conditions

Other studies related to the condition(s) this trial covers.